CA

Cardiogeni Plc

Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BTBLFC12
LEI:
9845000F8F59ATZD8F92
Country:
United Kingdom
Address:
Celixir House Stratford-Upon-Avon Business & Technology Park, CV37 7GZ Stratford-Upon-Avon
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Cardiogeni Plc is a clinical-stage biotechnology company, founded by Nobel Laureate Professor Sir Martin Evans, that focuses on developing next-generation treatments for heart failure. The company specializes in regenerative medicine, utilizing a proprietary platform technology to create engineered cellular medicines. These therapies are designed to treat patients with heart failure, particularly those undergoing coronary artery bypass surgery. Cardiogeni's lead product candidate is CLXR-001. The company's mission is to become a market leader in heart failure regeneration by developing a new class of life-saving treatments.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Cardiogeni Plc. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-24 17:45
Share Issue/Capital Change
Details of Advanced Subscription & Company Update
English 21.0 KB
2025-07-24 08:00
Capital/Financing Update
£150,000 Advanced Subscription Agreement
English 14.2 KB
2025-07-02 08:00
Regulatory News Service
Appointment of corporate broker
English 11.6 KB

Automate Your Workflow. Get a real-time feed of all Cardiogeni Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cardiogeni Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A